Eric Lefkofsky Sells 22,335 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 22,335 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $984,303.45. Following the completion of the sale, the chief executive officer directly owned 2,230,721 shares in the company, valued at approximately $98,307,874.47. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

NASDAQ:TEM traded up $0.61 during mid-day trading on Thursday, hitting $46.49. 3,802,434 shares of the company’s stock traded hands, compared to its average volume of 5,629,236. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The company has a market cap of $8.35 billion, a PE ratio of -27.03 and a beta of 3.99. The firm’s 50 day simple moving average is $49.11 and its 200 day simple moving average is $59.69. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period in the prior year, the business earned ($0.24) earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. Sell-side analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on TEM. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. HC Wainwright cut their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Robert W. Baird initiated coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective for the company. BTIG Research dropped their price objective on Tempus AI from $90.00 to $80.00 and set a “buy” rating for the company in a report on Friday, May 8th. Finally, Jefferies Financial Group initiated coverage on Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.64.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Tempus AI by 1,459.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock worth $8,174,000 after purchasing an additional 94,783 shares in the last quarter. Vanguard Group Inc. grew its stake in Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in Tempus AI in the third quarter worth about $1,695,000. Krane Funds Advisors LLC grew its stake in Tempus AI by 218.2% in the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock worth $2,427,000 after purchasing an additional 19,358 shares in the last quarter. Finally, Aberdeen Group plc grew its stake in Tempus AI by 64.2% in the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock worth $15,530,000 after purchasing an additional 102,878 shares in the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.